Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Archer

Showing results (61-70 of 200) with videos related to

Pageof 20
Sort By:
Menopause (New York, N.Y.)|March 7, 2018
Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal womenKelly M Tucker, Keshav Godha, Sebastian Mirkin, et al.
Contraception|January 18, 2015
A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age womenAnh Dinh, Intira Sriprasert, Alistair R Williams, et al.
International Journal of Molecular Sciences|July 27, 2024
Validation of an In Vitro Diagnostic Test for Endometriosis: Impact of Confounding Medical Conditions and Lesion LocationElza Daoud, David F Archer, Fabio Parazzini, et al.
Contraception|August 6, 2023
The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese usersMitchell D Creinin, Alicyoy Angulo, Enrico Colli, et al.
Contraception|December 12, 2012
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patchFrank Z Stanczyk, David F Archer, Arkady Rubin, et al.
Contraception|August 25, 2009
Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimenDavid F Archer, George Kovalevsky, Susan A Ballagh, et al.
Menopause (New York, N.Y.)|August 22, 2013
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal womenDavid F Archer, Thomas Schmelter, Matthias Schaefers, et al.
Menopause (New York, N.Y.)|June 23, 2017
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopauseFernand Labrie, David F Archer, Céline Martel, et al.
American Journal of Obstetrics and Gynecology|September 16, 2014
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese womenAndrew M Kaunitz, David F Archer, Daniel R Mishell, et al.
Contraception|February 19, 2004
The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacyDavid F Archer, Vanessa Cullins, George W Creasy, et al.
Pageof 20

Showing results (61-70 of 200) with videos related to

Sort By:
Pageof 20
Menopause (New York, N.Y.)|March 7, 2018
Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal womenKelly M Tucker, Keshav Godha, Sebastian Mirkin, et al.
Contraception|January 18, 2015
A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age womenAnh Dinh, Intira Sriprasert, Alistair R Williams, et al.
International Journal of Molecular Sciences|July 27, 2024
Validation of an In Vitro Diagnostic Test for Endometriosis: Impact of Confounding Medical Conditions and Lesion LocationElza Daoud, David F Archer, Fabio Parazzini, et al.
Contraception|August 6, 2023
The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4 mg (24/4-day regimen) in obese usersMitchell D Creinin, Alicyoy Angulo, Enrico Colli, et al.
Contraception|December 12, 2012
Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patchFrank Z Stanczyk, David F Archer, Arkady Rubin, et al.
Contraception|August 25, 2009
Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimenDavid F Archer, George Kovalevsky, Susan A Ballagh, et al.
Menopause (New York, N.Y.)|August 22, 2013
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal womenDavid F Archer, Thomas Schmelter, Matthias Schaefers, et al.
Menopause (New York, N.Y.)|June 23, 2017
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopauseFernand Labrie, David F Archer, Céline Martel, et al.
American Journal of Obstetrics and Gynecology|September 16, 2014
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese womenAndrew M Kaunitz, David F Archer, Daniel R Mishell, et al.
Contraception|February 19, 2004
The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacyDavid F Archer, Vanessa Cullins, George W Creasy, et al.
Pageof 20